Global Rare Disease Drugs Market Outlook, 2031

The global rare disease drugs industry covers medicines for diseases that affect small numbers of people, defined in the United States as conditions affecting fewer than 200,000 people and in the European Union as conditions affecting no more than five in 10,000 people. There are more than 7,000 known rare diseases, affecting an estimated 300 million people worldwide, and about 70% begin in childhood. Most are genetic, and many are severe, progressive and life-threatening, yet only about 5% have an approved treatment. Rare disease drugs, often called orphan drugs, benefit from incentives such as the US Orphan Drug Act, which offers seven years of market exclusivity, tax credits and fee waivers, and the EU's orphan medicinal products regulation, which offers ten years of exclusivity. The market includes enzyme replacement therapies, small molecules, monoclonal antibodies, antisense oligonucleotides, siRNA drugs, gene therapies, gene editing and cell therapies. Leading companies include Sanofi, with its Genzyme rare disease business; AstraZeneca, with Alexion; Vertex, with cystic fibrosis and sickle cell therapies; Novartis; Roche; Takeda; BioMarin; Alnylam; Ionis; Sarepta; Biogen; Ultragenyx; Sobi; Amgen, after acquiring Horizon; Pfizer; Regeneron; Chiesi; Jazz; PTC Therapeutics; and many smaller biotechnology companies.

Rare diseases have become one of the most important growth areas in the pharmaceutical industry. Orphan drugs now account for about half of new drug approvals by the FDA in many years, and they command some of the highest prices in medicine. Scientific advances have enabled treatments that address root causes: Vertex's triple combination Trikafta transformed cystic fibrosis, Alnylam's siRNA drugs treat transthyretin amyloidosis, and gene therapies such as Zolgensma for spinal muscular atrophy and Casgevy, the first CRISPR-based therapy, approved in December 2023 for sickle cell disease, offer potential one-time treatments. In May 2025, doctors in Philadelphia reported treating an infant with a personalised base-editing therapy designed for his specific mutation, showing the potential of bespoke genetic medicines. Regulators have adapted, with the FDA introducing its Rare Disease Evidence Principles in September 2025 to support approvals based on a single adequate trial plus confirmatory evidence for very rare genetic diseases. US legislation in July 2025, the ORPHAN Cures Act included in the One Big Beautiful Bill Act, exempted drugs approved for multiple rare diseases from Medicare price negotiation. Challenges remain significant, including gene therapy safety concerns such as patient deaths linked to Sarepta's Elevidys in 2025, the commercial withdrawal of several gene therapies because of weak uptake, high prices that strain payers, and regulatory unpredictability during changes at the FDA in 2025.

Market Dynamics Market Drivers • Advances in Genetics and New Treatment ModalitiesFalling costs of genome sequencing and newborn screening have made it easier to diagnose rare genetic diseases, and understanding of their causes has grown rapidly. New modalities, including antisense oligonucleotides, siRNA, gene therapy, gene editing and mRNA, can target the underlying genetic defect. These technologies allow companies to develop treatments for diseases that were previously untreatable, and platform approaches can be adapted across many related diseases.
• Regulatory and Commercial IncentivesOrphan drug designations provide market exclusivity, tax credits, fee waivers and access to expedited review pathways such as breakthrough therapy, accelerated approval and priority review. Regulators have shown flexibility on evidence for small populations, including the FDA's Rare Disease Evidence Principles. Premium pricing, smaller clinical trials, strong patient advocacy and lower competition make rare diseases attractive to investors and large pharmaceutical companies.

Market Challenges • High Costs and Reimbursement PressureRare disease drugs are among the most expensive medicines, with annual costs often above USD 300,000 and gene therapies priced at USD 2 million to more than USD 4 million. Payers and health technology assessment bodies question value and budget impact, and some countries delay or refuse reimbursement. Outcomes-based agreements and instalment payments are being tested, but access varies widely, and several gene therapies were withdrawn from markets because of poor commercial uptake.
• Diagnostic Delays and Development DifficultiesRare disease patients often wait years for a correct diagnosis, reducing the number of treated patients and delaying treatment. Small and dispersed patient populations make clinical trials difficult to recruit and design, and natural history data are often lacking. Safety risks with new modalities, including liver toxicity and deaths associated with some gene therapies, can lead to clinical holds and restrictions, increasing development risk.

Market Trends • Personalised and Platform Genetic MedicinesResearchers and companies are developing platform approaches that allow genetic medicines to be adapted quickly for different mutations, including personalised antisense oligonucleotides and base-editing therapies designed for individual patients. The successful treatment of an infant with a bespoke base-editing therapy in 2025 has encouraged regulators and developers to consider new pathways for ultra-rare diseases. Non-profit organisations and academic consortia are exploring ways to make such treatments sustainable.
• Newborn Screening and Earlier TreatmentExpanded newborn screening using genomic sequencing is being piloted in the United States, the UK and other countries, allowing diseases such as spinal muscular atrophy to be treated before symptoms appear. Earlier diagnosis improves outcomes for many rare diseases and increases the number of patients eligible for treatment. AI tools are also helping clinicians recognise rare disease patterns in medical records and facial features, shortening diagnostic journeys.



Segment Analysis Biologics, including enzyme replacement therapies and monoclonal antibodies, account for a large share of rare disease drug value, while genetic medicines such as antisense, siRNA and gene therapies are the fastest-growing modalities. Small molecules remain important in rare diseases, including cystic fibrosis transmembrane conductance regulator modulators, oral therapies for spinal muscular atrophy, transthyretin stabilisers, substrate reduction therapies for lysosomal storage disorders and treatments for rare cancers and metabolic diseases. Biologics include enzyme replacement therapies for Gaucher, Fabry, Pompe, mucopolysaccharidosis and other lysosomal storage diseases, monoclonal antibodies such as complement inhibitors for paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, and protein therapies for haemophilia and other conditions. Antisense oligonucleotides, such as nusinersen, tofersen and eplontersen, modify RNA processing or reduce toxic proteins. siRNA drugs, such as patisiran, vutrisiran, givosiran, lumasiran and fitusiran, silence disease-causing genes and are dosed infrequently. Gene therapies, such as onasemnogene abeparvovec, etranacogene dezaparvovec, valoctocogene roxaparvovec and voretigene neparvovec, deliver functional genes. Gene editing, including CRISPR-based Casgevy and emerging base and prime editing therapies, corrects genetic defects. Cell therapies, including engineered stem cells and CAR-T cells, treat some rare blood and immune disorders. mRNA therapies are in development for rare metabolic diseases. Repurposed drugs and dietary treatments form additional segments.

Rare oncology and rare hematology represent large shares of the rare disease drug market, while neurology, metabolic and genetic disorders are among the fastest-growing therapeutic areas. Rare cancers, including many hematological malignancies and genetically defined solid tumours, account for a substantial share of orphan drug approvals and revenue, as many targeted cancer therapies qualify for orphan status. Rare hematology diseases, including haemophilia, sickle cell disease, thalassaemia, paroxysmal nocturnal haemoglobinuria and immune thrombocytopenia, are treated with high-value biologics, siRNA drugs and gene therapies. Rare neurological and neuromuscular diseases, including spinal muscular atrophy, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, Huntington's disease, Friedreich's ataxia, Rett syndrome and rare epilepsies, have seen many new approvals and are active areas of genetic medicine. Metabolic and lysosomal storage disorders, including phenylketonuria, Gaucher, Fabry and Pompe diseases and urea cycle disorders, are treated with enzyme replacement therapy, substrate reduction therapy and gene therapy. Rare respiratory diseases, especially cystic fibrosis, form one of the most valuable segments, dominated by Vertex. Rare immunological and inflammatory diseases, including hereditary angioedema, myasthenia gravis and immunodeficiencies, are growing. Transthyretin amyloidosis has become a major market. Rare endocrine, renal, ophthalmic and cardiovascular diseases form further segments.

Injectable and infused therapies account for most rare disease drug value, while oral therapies and one-time gene therapies are changing treatment patterns. Intravenous infusions are used for enzyme replacement therapies, many monoclonal antibodies, gene therapies and some chemotherapy regimens, often given every one to four weeks at infusion centres or at home by nurses. Subcutaneous injections are used for many biologics and siRNA drugs, which can be given every three to six months, and for self-administered treatments such as hereditary angioedema prophylaxis, improving convenience. Oral therapies, including cystic fibrosis modulators, risdiplam for spinal muscular atrophy, tafamidis and acoramidis for transthyretin amyloidosis and substrate reduction therapies, allow treatment at home. Intrathecal injection into the spinal fluid is required for some antisense drugs, such as nusinersen and tofersen. Subretinal injection is used for ocular gene therapy. One-time gene therapies and gene editing treatments are given by intravenous infusion, sometimes after chemotherapy conditioning, and they aim to replace lifelong treatment. Inhaled therapies are used in some rare lung diseases. The move toward less frequent dosing, oral options and one-time treatments reduces the burden for patients and caregivers, although it changes the economics of chronic therapy.

Hospital pharmacies and specialty pharmacies are the main distribution channels for rare disease drugs, supported by specialist treatment centres and home infusion services. Hospital pharmacies supply infused therapies, gene therapies and treatments for acute and complex rare diseases, and specialist centres of excellence coordinate diagnosis and care for conditions such as cystic fibrosis, haemophilia, lysosomal storage disorders and neuromuscular diseases. Gene therapies are delivered only at qualified treatment centres. Specialty pharmacies distribute high-cost oral and self-injected rare disease drugs, often through limited distribution networks chosen by manufacturers to manage patient support, reimbursement and data collection. Home infusion services allow patients receiving enzyme replacement therapy and other infusions to be treated at home. Manufacturer patient support programmes help families navigate insurance, travel and financial assistance. Government procurement and national rare disease programmes fund treatments in many countries, and some operate managed access schemes that provide drugs while evidence is collected. Named patient and early access programmes supply unapproved drugs to patients with no alternatives. Compassionate use and expanded access programmes supply investigational therapies. Patient advocacy organisations play an important role in diagnosis, trial recruitment and access.

Regional Analysis North America leads the rare disease drugs market because of high prices, the Orphan Drug Act's incentives, flexible regulatory pathways and a large rare disease biotechnology industry, while Europe is the second largest market and Asia-Pacific is expanding rapidly. North America, led by the United States, accounts for the largest share of rare disease drug revenue. The US Orphan Drug Act, FDA expedited pathways and high prices have made the United States the first launch market for most rare disease therapies, and the country has the largest concentration of rare disease biotechnology companies. In 2025, the FDA introduced its Rare Disease Evidence Principles and Congress passed the ORPHAN Cures Act, exempting multi-indication orphan drugs from Medicare negotiation, while safety issues with Elevidys and changes in FDA leadership created uncertainty. Canada launched a national strategy for drugs for rare diseases in 2023. Europe is the second largest market, supported by EU orphan regulation and national rare disease plans, though health technology assessment and pricing negotiations can delay access and vary by country. Proposed EU pharmaceutical legislation would modify orphan exclusivity. Germany, France, Italy, the UK and Spain are the largest European markets. Asia-Pacific is growing quickly, with Japan's orphan drug system and relatively fast approvals, China's national rare disease list and inclusion of orphan drugs in national reimbursement negotiations, and expanding access in South Korea, Australia and Taiwan. India launched a National Policy for Rare Diseases in 2021 with limited funding. Latin America has growing rare disease programmes, often driven by court orders for access in Brazil and Colombia. The Middle East, particularly Saudi Arabia and the Gulf states, has high rates of inherited diseases due to consanguinity and is investing in genetic screening and advanced therapies.

Key Developments September 2025: The FDA outlined a process allowing approval of drugs for very rare genetic diseases based on one adequate and well-controlled trial plus robust confirmatory evidence.
July 2025: US legislation exempted drugs approved for one or more rare diseases from Medicare price negotiation, strengthening incentives to develop treatments for multiple orphan indications.
July 2025: Following deaths from acute liver failure, the FDA requested a pause in some Elevidys shipments and required safety labelling changes for the Duchenne gene therapy.
May 2025: Researchers at Children's Hospital of Philadelphia and Penn Medicine reported treating an infant with CPS1 deficiency using a base-editing therapy designed for his specific mutation.
February 2025: Pfizer ended commercialisation of its haemophilia B gene therapy, citing weak demand, one of several gene therapy withdrawals for commercial reasons.
December 2023: Vertex and CRISPR Therapeutics' Casgevy was approved for sickle cell disease, becoming the first approved medicine based on CRISPR gene editing.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Rare Disease Drugs Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Type
• Small Molecules
• Biologics
• Antisense Oligonucleotides
• siRNA Therapies
• Gene Therapies and Gene Editing
• Cell Therapies

By Therapeutic Area
• Rare Oncology
• Rare Hematology
• Rare Neurology and Neuromuscular Diseases
• Metabolic and Lysosomal Storage Disorders
• Rare Respiratory Diseases
• Rare Immunology

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intrathecal and Other

By Distribution Channel
• Hospital Pharmacies
• Specialty Pharmacies
• Home Infusion Services
• Government and Managed Access Programmes